Animal & Veterinary
ANADA 200-251 Sulforal® - original approval
Approval Date: August 3, 1998
I. GENERAL INFORMATION
|Sponsor:||Med Pharmex, Inc.|
|Dosage Form:||Oral solution|
|Composition:||3.75 gram sulfadimethoxine solubilized with sodium hydroxide|
|Method of Administration:||Oral in drinking water|
|Species:||Chicken, Turkeys, Dairy Calves, Dairy Heifers and Beef Cattle|
|Packaging:||1 gallon (128 fl. oz.) bottle|
|Indication for Use:|
Broiler and Replacement Chickens:
Dairy Calves, Dairy Heifers and Beef Cattle:
|Pioneer Product:||Pfizer’s Albon® 12.5% Concentrated Solution (NADA 31-205)|
|Patents/Exclusivity:||The drug is listed in the GREEN BOOK. There are no unexpired patents listed in the GREEN BOOK, and no exclusivity protection for Albon®.|
II. TARGET ANIMAL SAFETY AND DRUG EFFECTIVENESS
Under the provisions of the Federal Food, Drug and Cosmetic Act, as amended by the Generic Animal Drug and Patent Term Restoration Act (53 FR 50460, December 15, 1988, First GADPTRA Policy Letter) an abbreviated new animal drug application (ANADA) may be submitted for a generic version of an approved new animal drug (pioneer product). New target animal safety data, drug effectiveness data, and human food safety data (other than tissue residue data) are not required for approval of an ANADA. An ANADA relies on the target animal safety, drug effectiveness, and human food safety data in the pioneer’s new animal drug applications. Ordinarily, the ANADA sponsor shows that the generic product is bioequivalent to the pioneer. If bioequivalence is demonstrated through a clinical end-point study, then a tissue residue study to establish the withdrawal time for the generic product is also required. For certain dosage forms, the agency will grant a waiver from conducting an in vivo bioequivalence study (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, April 1996).
Based on the formulation characteristics of the generic product, Med-Pharmex, Inc., was granted a waiver from the requirement on an in vivo bioequivalence study for the generic product Sulfadimethoxine 12.5% Oral Solution. The generic product is administered as an oral solution and contains the same active and inactive ingredients in the same concentration as the pioneer product.
III. HUMAN FOOD SAFETY
The tolerances (21 CFR 556.640) established for the pioneer product apply to the generic product. Tolerances are established for residues of sulfadimethoxine in uncooked edible tissues of chickens, turkeys, and cattle as follows: 0.1 part per million (negligible residue).
When a waiver from the requirement of an in vivo bioequivalence study is granted, the withdrawal times are those previously assigned to the pioneer product. The withdrawal times for sulfadimethoxine 12.5% Oral Solution in medicated drinking water are established under:
- 21 CFR 520.2220a (e) (1) (iii): Broiler and Replacement Chickens-5 days before slaughter.
- 21 CFR 520.2220 a(e) (2) (iii): Meat-Producing Turkeys-5 days before slaughter.
- 21 CFR 520.2220 a(e) (3) (iii): Dairy Calves, Dairy Heifers and Beef Cattle-7 days before slaughter.
Regulatory Method for Residues
The regulatory analytical method for detection of residues of the drug is a thin layer densitometric procedure. This method is found in the Official Methods of Analysis of AOAC International, 16th edition.
Human Safety Relative to Possession, Handling and Administration
Labeling contains adequate caution/warning statements.
IV. AGENCY CONCLUSIONS
This ANADA submitted under section 512(b)(2) of the Federal Food, Drug, and Cosmetic Act satisfies the requirements of sections 512(n) of the Act and demonstrates that Sulforal® Oral Solution (3.75 gram sulfadimethoxine solubilized with sodium hydroxide) when used under its proposed conditions of use, is safe and effective for the labeled indications.
- Generic Labeling: 1 gallon (128 fl oz) container label
- Pioneer Labeling: 3.785 L (1 Gal) container label